Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS ) 21.79 -0.41 (-1.85%) Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 36,285 Open 21.90 Bid (Size) 17.78 (11) Ask (Size) 21.73 (4) Prev. Close 22.20 Today's Range 21.74 - 22.48 52wk Range 5.633 - 26.35 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 May 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Performance YTD +82.34% +82.34% 1 Month +11.12% +11.12% 3 Month +8.95% +8.95% 6 Month +113.63% +113.63% 1 Year +58.13% +58.13% More News Read More 12 Health Care Stocks Moving In Monday's After-Market Session April 29, 2024 Via Benzinga NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease April 09, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer April 01, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress March 25, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD March 12, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update February 28, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March February 26, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday January 19, 2024 Via Benzinga Topics Stocks Exposures US Equities Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 19, 2024 Via Benzinga Cholesterol Player NewAmsterdam Pharma's Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says January 16, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session January 15, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session January 10, 2024 Via Benzinga Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 10, 2024 Via Benzinga NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors January 08, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces 2024 Strategic Priorities January 04, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights November 13, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's After-Market Session October 31, 2023 Via Benzinga FMC, Li-Cycle Holdings, Okta And Other Big Stocks Moving Lower On Monday October 23, 2023 Via Benzinga Topics Stocks Exposures US Equities Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session October 23, 2023 Via Benzinga NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer October 23, 2023 From NewAmsterdam Pharma N.V Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
